Acadia Pharmaceuticals has been granted a patent for an improved method of making carbetocin drug products with increased resistance to aggregation. The method involves agitating a carbetocin preparation, filtering off aggregates, and ensuring content uniformity over time. The drug product can be used for treating neurodevelopmental disorders like Präder-Willi syndrome. GlobalData’s report on Acadia Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Acadia Pharmaceuticals Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Acadia Pharmaceuticals, Human telomerase RT biomarker was a key innovation area identified from patents. Acadia Pharmaceuticals's grant share as of January 2024 was 36%. Grant share is based on the ratio of number of grants to total number of patents.

Improved carbetocin drug product with increased resistance to aggregation

Source: United States Patent and Trademark Office (USPTO). Credit: Acadia Pharmaceuticals Inc

A recently granted patent (Publication Number: US11844764B2) discloses a method for preparing a carbetocin drug product with increased resistance to aggregation. The method involves dissolving carbetocin or its salt with various excipients to form an aqueous solution, agitating the solution to form aggregate-forming solids, removing the solids, and adding the solution to a container to create the final drug product. This process results in a carbetocin drug product that shows enhanced resistance to aggregation when subjected to shaking stress, compared to untreated carbetocin solutions.

Furthermore, the patent claims specify the use of specific excipients such as surface active agents like cellulose derivatives, solubilizers like hydrotropes, amino acids, or cyclodextrins, and other additives like tonicity enhancers and pH adjusters. The concentration ranges for these components are also detailed in the claims, ensuring the reproducibility and effectiveness of the method. By following this method, the resulting carbetocin drug product is expected to be substantially free of aggregate-forming solids, providing a stable and reliable formulation for potential pharmaceutical applications.

To know more about GlobalData’s detailed insights on Acadia Pharmaceuticals, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies